In this prospective cohort study of 461 women, there was no association between intrauterine device use and time to conception (hazard ratio, 1.25; 95% confidence interval, 0.99-1.58). However, past Mycoplasma genitalium infection was found to be associated with longer times to conception and lower conception rates by 12 months (68% vs. 80%, P = 0.02).
Financial and public relations risks are obstacles to their inclusion
March 24, 2021
On Feb. 18, Pfizer and BioNTech announced they would dose about 4,000 healthy pregnant women with the COVID-19 vaccine to evaluate its safety, tolerability, and immunogenicity. Although pregnant people were excluded initially from the COVD-19 trials, research has shown they are at higher risk for more severe disease.
A meta-analysis and systematic review that included 24 studies mostly from China found that the rates of preterm birth and cesarean delivery were higher in women with COVID-19 compared to international averages.
Twenty-five women with perinatal attention-deficit hyperactivity disorder were followed prospectively during pregnancy for changes in anxiety, depression, perceived stress, and functional impairment. Statistically significant differences in mood and functional impairment in the family domain were found in those who discontinued their psychostimulant.
Pregnant women, some of them healthcare workers, are dying at high rates after contracting COVID-19. The COVID-19 vaccine risk is unknown because pregnant women were not included in early clinical trials. However, the emerging data on the threat of COVID-19 infection during pregnancy is tilting the risk-benefit equation.
An analysis of the Women’s Health Study based on a recent questionnaire about adverse pregnancy outcomes showed hypertensive disorders of pregnancy and low birth weight are independent predictors of subsequent atherosclerotic cardiovascular disease.
In this double-blind, randomized clinical trial, 406 pregnant women were randomized to dydrogesterone or placebo. There were no statistically significant differences in the primary outcome (miscarriage before 20 weeks of gestation; relative risk, 0.897; 95% confidence interval, 0.548-1.467; P = 0.772), which occurred in 12.8% and 14.3% in the dydrogesterone and placebo arms, respectively. The use of dydrogesterone in women with threatened miscarriage for the prevention of early pregnancy loss in the first trimester failed to decrease the miscarriage rate or increase the live birth rate.